Key result
Three-year event-free survival was 44.0% for CIC-fused and 41.2% for BCOR-rearranged soft tissue sarcomas (p=0.97), reflecting dismal overall outcomes for these rare pediatric tumors.
Cohort (n=60)
Yes
Absolute Event Rate: 44% vs 41.2%
p-value: p=0.97
Pediatric patients with CIC-fused and BCOR-rearranged soft tissue sarcomas often present with large tumors and metastatic disease, and have a dismal overall outcome.
No takes yet. Share an insight, caveat, or question.
Outcomes remain poor in these rare sarcomas; leaves open need for prospective trials before changing practice.
Sparber‐Sauer et al. (2023) conducted a cohort in CIC-fused and BCOR-rearranged soft tissue sarcomas (n=60). CIC-fused soft tissue sarcomas vs. BCOR-rearranged soft tissue sarcomas was evaluated on Three-year event-free survival (p=0.97). Three-year event-free survival was 44.0% for CIC-fused and 41.2% for BCOR-rearranged soft tissue sarcomas (p=0.97), reflecting dismal overall outcomes for these rare pediatric tumors.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: